Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | POLL | Q9UGP5 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | S100A4 | P26447 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PTK2 | Q05397 | 10/20 | 0.47 |
| ▸ | TOP1 | P11387 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL266877 | 0.89 | POLL (0.50) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL23023381 | 0.89 | POLL (0.50) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL34467006 | 0.84 | POLL (0.53) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL2047592 | 0.82 | TOP1 (0.47) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL2046418 | 0.81 | ABCB1 (0.49) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL8736314 | 0.81 | ALDH1A1 (0.56) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL11242332 | 0.80 | PTK2 (0.40) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL12634878 | 0.78 | ABCB1 (0.49) | MEN1KMT2APTK2ABCB1 | |
| SCHEMBL1758362 | 0.77 | PTK2 (0.51) | PTK2ABCB1 | |
| SCHEMBL28463150 | 0.77 | CYP19A1 (0.46) | POLLCYP19A1CYP11B1CYP11B2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617786-B2 | Dihydro-cyclopenta-isoquinoline sulfonamides derivatives | UCB Biopharma SRL (BE) | 2026-05-05 | — | — | US | disclosed |
| EP-4081295-B1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE SULFONAMIDES DERIVATIVES | UCB Biopharma SRL (BE) | 2026-04-29 | — | — | EP | disclosed |
| US-20260103475-A1 | MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORP (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4660185-A1 | NAV1.7- AND/OR NAV1.8-INHIBITING AMIDES, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS | Eurofarma Laboratórios S.A. (BR) | 2025-12-10 | — | — | EP | disclosed |
| CN-115279771-B | MAP4K1 inhibitors | 缆图药品公司 | 2025-03-21 | — | — | CN | disclosed |
| US-12202844-B2 | MAP4K1 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2025-01-21 | — | — | US | disclosed |
| US-12042495-B2 | MAP4K1 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240199648-A1 | MAP4K1 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2024-06-20 | — | — | US | disclosed |
| EP-4370523-A1 | HETEROCYCLIC COMPOUNDS AS MAP4K1 INHIBITORS | Blueprint Medicines Corporation (US) | 2024-05-22 | — | — | EP | disclosed |
| CN-117940438-A | Heterocyclic compounds as MAP4K1 inhibitors | 缆图药品公司 | 2024-04-26 | — | — | CN | disclosed |
| US-5693647-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-02 | — | — | US | disclosed |
| US-5693646-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-12-02 | — | — | US | disclosed |
| US-5688808-A | Steroid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1997-11-18 | — | — | US | disclosed |
| EP-0800519-A1 | STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 1997-10-15 | — | — | EP | disclosed |
| US-5646173-A | ANTISEROTONINE AGENTS; CENTRAL NERVOUS SYSTEM DISORDERS; ANTIDEPRESSANTS | HOFFMANN-LA ROCHE INC. (US) | 1997-07-08 | — | — | US | disclosed |
| WO-1996019458-A2 | STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1996-06-27 | — | — | WO | disclosed |
| EP-0657426-A2 | Tricyclic pyrrole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1995-06-14 | — | — | EP | disclosed |
| EP-0281261-B1 | 3-AMINOMETHYL DERIVATIVES OF INDANE, INDOLINE AND DIHYDROBENZOFURANE AND DIHYDROBENZOTHIOPHENE | H. LUNDBECK A/S (DK) | 1992-05-06 | — | — | EP | disclosed |
| US-4946863-A | CNS-affecting 6-oxy-3-aminomethyl indanes, compositions thereof, and method of treating therewith | H. LUNDBECK A/S (DK) | 1990-08-07 | — | — | US | disclosed |
| US-4847254-A | CNS affecting 5-oxy-3-aminomethyl-dihydro-benzofurans and benzothiophenes | H. LUNDBECK A/S (DK) | 1989-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12617786-B2 | Dihydro-cyclopenta-isoquinoline sulfonamides derivatives | HRH2, HRH4, HRH1 | KDM4E 3732/4885ALDH1A1 1965/4885GLA 3708/4885 |
| US-12202844-B2 | MAP4K1 inhibitors | MAP4K1, MAP4K4, MAP4K2 | KDM4E 834/4885ALDH1A1 2180/4885GLA 3501/4885 |
| US-20240199648-A1 | MAP4K1 INHIBITORS | MAP4K1, MAP4K4, MAP4K2 | KDM4E 834/4885ALDH1A1 2180/4885GLA 3501/4885 |
| US-20260103475-A1 | MAP4K1 INHIBITORS | MAP4K1, MAP3K4, MAP4K4 | KDM4E 842/4885ALDH1A1 2915/4885GLA 4584/4885 |
| US-12042495-B2 | MAP4K1 inhibitors | MAP4K1, MAP4K4, MAP4K2 | KDM4E 676/4885ALDH1A1 2194/4885GLA 3668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.